Polarean Imaging PLC Grant of options (7207S)
08 Noviembre 2019 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 7207S
Polarean Imaging PLC
08 November 2019
8 November 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Grant of Options
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with a proprietary drug-device combination product,
announces that upon the recommendation of the Company's
Remuneration Committee it has granted options over a total of
1,410,750 ordinary shares of GBP0.00037 in the capital of the
Company (the "Ordinary Shares") to certain employees of the Company
pursuant to the terms of the Company's Stock Option Plan (the
"Share Options").
1,200,000 Share Options have been granted to Mr. Alexander
Dusek, the Company's recently appointed Vice-President of
Commercialisation. These Share Options will be exercisable at a
price of 23p. 300,000 of the Share Options will vest on 23 October
2020 with the remaining 900,000 Share Options vesting in equal
portions on the last day of each calendar month over the period of
36 months starting on 30 November 2020.
The remaining 210,750 Share Options will be exercisable at a
price of 23p, with 25% of the options vesting on 3 June 2020 and
the remaining 75% of the options vesting in equal portions on the
last day of each calendar month over the period of 36 months
starting on 31 July 2020.
Following the grant of the Share Options referred to above,
there are 22,445,072 outstanding options and warrants over
Polarean's Ordinary Shares, representing 16.4% of the Company's
Ordinary Shares and total voting rights on a fully diluted
basis.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell, Soltan Tagiev (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities/person
1. closely associated
a) Name: Alexander Dusek
--------------------------------- ------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status: Vice-President of Commercialization
(PDMR, non-board role)
--------------------------------- ------------------------------------
b) Initial notification/Amendment: Initial notification
--------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name: Polarean Imaging Plc
--------------------------------- ------------------------------------
b) LEI: 213800DGR2BHXJ36OL37
--------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of the financial Options over ordinary
instrument, type of instrument: shares of GBP0.00037
Identification code: GB00BF3DT583
--------------------------------- ------------------------------------
b) Nature of the transaction: Grant of options over
ordinary shares
--------------------------------- ------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
23p 1,200,000
----------
--------------------------------- ------------------------------------
d) Aggregated information: Price(s) Volume(s)
Aggregated volume: 23p 1,200,000
Price: ----------
--------------------------------- ------------------------------------
e) Date of the transaction: 2019-11-06
--------------------------------- ------------------------------------
f) Place of the transaction: Outside a trading venue
--------------------------------- ------------------------------------
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimise the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHDBBDBXGGBGCR
(END) Dow Jones Newswires
November 08, 2019 02:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024